Covered recipient · General Payments record
DAVID M SHEIN
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2018–2024
$5,181.39
- Reported across 239 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $367.67 | 15 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $61.86 | 3 |
| ABBVIE INC. | $55.66 | 2 |
| E.R. Squibb & Sons, L.L.C. | $54.17 | 2 |
| Amgen Inc. | $52.54 | 2 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $51.33 | 2 |
| Acerta Pharma LLC | $25.25 | 1 |
| Merck Sharp & Dohme Corporation | $24.45 | 1 |
| Medtronic, Inc. | $21.36 | 1 |
| SHIELD THERAPEUTICS INC | $21.05 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $25.68 | 07/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106080855 | CMS |
| ABBVIE INC. | $29.98 | 10/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106080857 | CMS |
| Amgen Inc. | $21.01 | 03/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117381170 | CMS |
| Amgen Inc. | $31.53 | 11/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111705492 | CMS |
| AstraZeneca Pharmaceuticals LP | $25.25 | 06/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105499496 | CMS |
| E.R. Squibb & Sons, L.L.C. | $26.18 | 03/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101671085 | CMS |
| E.R. Squibb & Sons, L.L.C. | $27.99 | 07/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101671145 | CMS |
| Medtronic, Inc. | $21.36 | 01/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1119368395 | CMS |
| Merck Sharp & Dohme LLC | $24.45 | 03/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141748995 | CMS |
| Novartis Pharmaceuticals Corporation | $26.64 | 02/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087279907 | CMS |
| Novartis Pharmaceuticals Corporation | $24.69 | 04/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087279929 | CMS |
| PFIZER INC. | $26.02 | 01/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131107242 | CMS |
| PFIZER INC. | $18.11 | 04/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131398827 | CMS |
| PFIZER INC. | $17.73 | 06/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131674150 | CMS |
| SHIELD THERAPEUTICS INC | $21.05 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150156459 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.